ZA984697B
(en)
*
|
1997-06-13 |
1999-12-01 |
Lilly Co Eli |
Stable insulin formulations.
|
US6211144B1
(en)
*
|
1998-10-16 |
2001-04-03 |
Novo Nordisk A/S |
Stable concentrated insulin preparations for pulmonary delivery
|
AU762351B2
(en)
|
1999-01-06 |
2003-06-26 |
Genentech Inc. |
Insulin-like growth factor (IGF) I mutant variants
|
DE60042550D1
(de)
|
1999-01-06 |
2009-08-27 |
Genentech Inc |
Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
|
ATE251466T1
(de)
*
|
1999-04-08 |
2003-10-15 |
Genentech Inc |
Zusammensetzung auf basis gegensätzlich geladener polypeptide
|
US20040220103A1
(en)
*
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
US6746853B1
(en)
|
1999-05-19 |
2004-06-08 |
Xencor, Inc. |
Proteins with insulin-like activity useful in the treatment of diabetes
|
US7169889B1
(en)
*
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
US7022674B2
(en)
*
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
US6734162B2
(en)
|
2000-01-24 |
2004-05-11 |
Minimed Inc. |
Mixed buffer system for stabilizing polypeptide formulations
|
EP1292324A2
(de)
*
|
2000-05-05 |
2003-03-19 |
Novo Nordisk A/S |
Neuropathien verursacht durch kritischen krankheiten
|
ES2301547T3
(es)
|
2000-05-16 |
2008-07-01 |
Genentech, Inc. |
Tratamiento de trastornos del cartilago.
|
US6867183B2
(en)
*
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7060675B2
(en)
*
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
AU2002248464A1
(en)
|
2001-02-21 |
2002-09-12 |
Medtronic Minimed, Inc. |
Stabilized insulin formulations
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6835802B2
(en)
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828297B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6737401B2
(en)
*
|
2001-06-28 |
2004-05-18 |
Metronic Minimed, Inc. |
Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
|
EP1412384B1
(de)
|
2001-06-28 |
2007-12-26 |
Novo Nordisk A/S |
Stabile formulierung von modifiziertem glp-1
|
US7196059B2
(en)
*
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US6770625B2
(en)
|
2001-09-07 |
2004-08-03 |
Nobex Corporation |
Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
|
US7166571B2
(en)
*
|
2001-09-07 |
2007-01-23 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7312192B2
(en)
*
|
2001-09-07 |
2007-12-25 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7030082B2
(en)
*
|
2001-09-07 |
2006-04-18 |
Nobex Corporation |
Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
|
US6913903B2
(en)
*
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US20030068361A1
(en)
*
|
2001-10-09 |
2003-04-10 |
Rimona Margalit |
Liposome-encapsulated insulin formulations
|
US20030199445A1
(en)
*
|
2002-02-07 |
2003-10-23 |
Knudsen Lotte Bjerre |
Use of GLP-1 compound for treatment of critically ill patients
|
AU2003236201A1
(en)
*
|
2002-05-07 |
2003-11-11 |
Novo Nordisk A/S |
Soluble formulations comprising monomeric insulin and acylated insulin
|
DE10227232A1
(de)
*
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
ITMI20021684A1
(it)
*
|
2002-07-29 |
2004-01-29 |
Therapicon Srl |
Composizione farmaceutica di peptide nasale
|
KR101123113B1
(ko)
*
|
2002-07-29 |
2012-03-15 |
쎄라피콘 에스.알.엘. |
코 펩티드 약학 제형
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
JP2007524592A
(ja)
|
2003-06-03 |
2007-08-30 |
ノボ・ノルデイスク・エー/エス |
安定化された薬学的ペプチド組成物
|
CA2545034C
(en)
|
2003-11-20 |
2013-03-05 |
Novo Nordisk A/S |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
EP2626368B1
(de)
|
2004-07-19 |
2016-12-21 |
Biocon Limited |
Insulinoligomerkonjugate, Formulierungen und Verwendungen davon
|
JP2008513356A
(ja)
*
|
2004-08-09 |
2008-05-01 |
アリオス バイオファーマ インク. |
合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
|
US7597884B2
(en)
*
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
EP1817048B1
(de)
|
2004-11-12 |
2014-02-12 |
Novo Nordisk A/S |
Stabile formulierungen insulinoptropischer peptide
|
CN101060856B
(zh)
*
|
2004-11-22 |
2011-01-19 |
诺和诺德公司 |
可溶、稳定的含胰岛素制剂
|
CA2593032C
(en)
|
2004-12-27 |
2015-12-22 |
Silence Therapeutics Ag |
Coated lipid complexes and their use
|
JPWO2006093222A1
(ja)
*
|
2005-03-02 |
2008-08-07 |
味の素株式会社 |
インスリンの多量体形成阻害剤
|
CN101180081B
(zh)
*
|
2005-05-25 |
2015-08-26 |
诺沃-诺迪斯克有限公司 |
稳定的多肽制剂
|
EP1888117A1
(de)
*
|
2005-05-25 |
2008-02-20 |
Novo Nordisk A/S |
Stabilisierte polypetidformulierungen
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
AU2006304757A1
(en)
*
|
2005-10-20 |
2007-04-26 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of rapid acting insulin
|
WO2007074133A2
(en)
|
2005-12-28 |
2007-07-05 |
Novo Nordisk A/S |
Compositions comprising an acylated insulin and zinc and method of making the said compositions
|
WO2007121318A2
(en)
*
|
2006-04-12 |
2007-10-25 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
US20090074852A1
(en)
*
|
2006-04-20 |
2009-03-19 |
Silence Therapeutics Ag |
Lipoplex formulations for specific delivery to vascular endothelium
|
EP1852108A1
(de)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Zusammensetzungen von DPP-IV-Inhibitoren
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
NZ573360A
(en)
|
2006-05-04 |
2012-08-31 |
Boehringer Ingelheim Int |
Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
|
WO2007135117A2
(en)
*
|
2006-05-24 |
2007-11-29 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations
|
US9023793B2
(en)
*
|
2006-09-29 |
2015-05-05 |
Retrophin, Inc. |
Intranasal carbetocin formulations and methods for the treatment of autism
|
GB0700523D0
(en)
*
|
2007-01-11 |
2007-02-21 |
Insense Ltd |
The Stabilisation Of Proteins
|
US8114428B2
(en)
*
|
2007-03-08 |
2012-02-14 |
Sbf Synthetic Bone Factory Gmbh |
Methods for manufacturing a composition for treating bone and/or cartilage defects
|
WO2008118387A2
(en)
*
|
2007-03-23 |
2008-10-02 |
Wayne State University |
Erythrocyte atp-release modulators
|
US20080260820A1
(en)
*
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
RU2453332C2
(ru)
*
|
2007-10-16 |
2012-06-20 |
Байокон Лимитид |
Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
|
US8986253B2
(en)
|
2008-01-25 |
2015-03-24 |
Tandem Diabetes Care, Inc. |
Two chamber pumps and related methods
|
AU2009226910B2
(en)
|
2008-03-18 |
2014-02-06 |
Novo Nordisk A/S |
Protease stabilized, acylated insulin analogues
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
ES2531657T3
(es)
|
2008-05-01 |
2015-03-18 |
Arecor Limited |
Formulación de una proteína
|
TWI451876B
(zh)
*
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
EP2328607A1
(de)
|
2008-07-16 |
2011-06-08 |
Arecor Limited |
Stabile formulierung eines therapeutischen proteins
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
JP2012502048A
(ja)
|
2008-09-08 |
2012-01-26 |
ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ |
アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
|
JP2012502081A
(ja)
|
2008-09-10 |
2012-01-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病及び関連症状の治療のための組み合わせ治療
|
US8408421B2
(en)
|
2008-09-16 |
2013-04-02 |
Tandem Diabetes Care, Inc. |
Flow regulating stopcocks and related methods
|
WO2010033878A2
(en)
|
2008-09-19 |
2010-03-25 |
David Brown |
Solute concentration measurement device and related methods
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
KR101939557B1
(ko)
|
2008-10-17 |
2019-01-17 |
사노피-아벤티스 도이칠란트 게엠베하 |
인슐린과 glp-1 효능제의 병용물
|
KR20110082180A
(ko)
|
2008-10-28 |
2011-07-18 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
알데히드 탈수소효소의 조절자 및 그것의 사용방법
|
AU2009309623B9
(en)
|
2008-10-30 |
2014-10-02 |
Novo Nordisk A/S |
Treating diabetes melitus using insulin injections with less than daily injection frequency
|
TWI508965B
(zh)
|
2008-12-23 |
2015-11-21 |
Boehringer Ingelheim Int |
有機化合物的鹽形式
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
CN105753965A
(zh)
|
2009-01-28 |
2016-07-13 |
斯马特塞尔斯公司 |
用于受控药物递送的基于缀合物的***
|
BRPI1007466A2
(pt)
|
2009-01-28 |
2018-06-12 |
Smartcells Inc |
conjugado de insulina cristalina, formulação de liberação prolongada, e, sistema de distribuição de bomba
|
WO2010088268A1
(en)
|
2009-01-28 |
2010-08-05 |
Smartcells, Inc. |
Exogenously triggered controlled release materials and uses thereof
|
JP2012516340A
(ja)
|
2009-01-28 |
2012-07-19 |
スマートセルズ・インコーポレイテツド |
合成コンジュゲートおよびその使用
|
MX2011008562A
(es)
|
2009-02-12 |
2011-09-09 |
Proyecto Biomedicina Cima Sl |
Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabolicas.
|
US9250106B2
(en)
|
2009-02-27 |
2016-02-02 |
Tandem Diabetes Care, Inc. |
Methods and devices for determination of flow reservoir volume
|
AU2010217760B2
(en)
|
2009-02-27 |
2015-04-09 |
Tandem Diabetes Care, Inc. |
Methods and devices for determination of flow reservoir volume
|
US8569231B2
(en)
|
2009-03-20 |
2013-10-29 |
Smartcells, Inc. |
Soluble non-depot insulin conjugates and uses thereof
|
EP2408808A4
(de)
|
2009-03-20 |
2015-05-06 |
Smartcells Inc |
Terminal-funktionalisierte konjugate und ihre verwendung
|
HUE027239T2
(en)
*
|
2009-06-26 |
2016-10-28 |
Novo Nordisk As |
Preparation containing insulin, nicotinamide and arginine
|
EP3284494A1
(de)
|
2009-07-30 |
2018-02-21 |
Tandem Diabetes Care, Inc. |
Tragbares infusionspumpensystem
|
PT3345593T
(pt)
|
2009-11-13 |
2023-11-27 |
Sanofi Aventis Deutschland |
Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
|
CN107308442B
(zh)
|
2009-11-13 |
2022-10-18 |
赛诺菲-安万特德国有限公司 |
包含glp-1激动剂、胰岛素和甲硫氨酸的药物组合物
|
JP2013512229A
(ja)
|
2009-11-27 |
2013-04-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療
|
CN101912600B
(zh)
*
|
2010-01-11 |
2014-01-29 |
杨国汉 |
改善胰岛素在溶液中稳定性的方法
|
NZ602921A
(en)
|
2010-05-05 |
2016-01-29 |
Boehringer Ingelheim Int |
Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
MX2012014247A
(es)
|
2010-06-24 |
2013-01-18 |
Boehringer Ingelheim Int |
Terapia para la diabetes.
|
AU2011282987A1
(en)
|
2010-07-28 |
2013-02-21 |
Smartcells, Inc. |
Recombinant lectins, binding-site modified lectins and uses thereof
|
AU2011282988A1
(en)
|
2010-07-28 |
2013-01-31 |
Smartcells, Inc. |
Recombinantly expressed insulin polypeptides and uses thereof
|
CA2805739A1
(en)
|
2010-07-28 |
2012-02-02 |
Smartcells, Inc. |
Drug-ligand conjugates, synthesis thereof, and intermediates thereto
|
LT2611458T
(lt)
|
2010-08-30 |
2016-12-27 |
Sanofi-Aventis Deutschland Gmbh |
Ave0010 panaudojimas gaminant vaistą, skirtą 2 tipo cukrinio diabeto gydymui
|
RU2013123515A
(ru)
|
2010-10-27 |
2014-12-10 |
Ново Нордиск А/С |
Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
CN102188367B
(zh)
*
|
2011-01-05 |
2012-11-07 |
山东新时代药业有限公司 |
一种甘精胰岛素注射液及其制备方法
|
WO2012149106A1
(en)
|
2011-04-29 |
2012-11-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for increasing proliferation of adult salivary stem cells
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
US20130011378A1
(en)
|
2011-06-17 |
2013-01-10 |
Tzung-Horng Yang |
Stable formulations of a hyaluronan-degrading enzyme
|
US20130345113A1
(en)
*
|
2011-07-13 |
2013-12-26 |
Ronald E. Strohbehn |
Method of Use of Activated Functional Proteins to Improve Animal Health
|
EP3517539B1
(de)
|
2011-07-15 |
2022-12-14 |
Boehringer Ingelheim International GmbH |
Substituiertes dimeres chinazolinderivat, dessen herstellung und dessen verwendung in pharmazeutischen zusammensetzungen zur behandlung von diabetes typ i und ii
|
MX370264B
(es)
|
2011-08-29 |
2019-12-09 |
Sanofi Aventis Deutschland |
Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
US9138479B2
(en)
*
|
2011-10-31 |
2015-09-22 |
Xeris Pharmaceuticals, Inc. |
Formulations for the treatment of diabetes
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
US9180242B2
(en)
|
2012-05-17 |
2015-11-10 |
Tandem Diabetes Care, Inc. |
Methods and devices for multiple fluid transfer
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US9555186B2
(en)
|
2012-06-05 |
2017-01-31 |
Tandem Diabetes Care, Inc. |
Infusion pump system with disposable cartridge having pressure venting and pressure feedback
|
US9707276B2
(en)
|
2012-12-03 |
2017-07-18 |
Merck Sharp & Dohme Corp. |
O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
|
NZ707160A
(en)
*
|
2012-12-19 |
2016-08-26 |
Wockhardt Ltd |
A stable aqueous composition comprising human insulin or an analogue or derivative thereof
|
WO2014102623A1
(en)
|
2012-12-26 |
2014-07-03 |
Wockhardt Limited |
Pharmaceutical composition
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
US10201656B2
(en)
|
2013-03-13 |
2019-02-12 |
Tandem Diabetes Care, Inc. |
Simplified insulin pump for type II diabetics
|
JP6410790B2
(ja)
|
2013-03-14 |
2018-10-24 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法
|
US9173998B2
(en)
|
2013-03-14 |
2015-11-03 |
Tandem Diabetes Care, Inc. |
System and method for detecting occlusions in an infusion pump
|
US9492608B2
(en)
|
2013-03-15 |
2016-11-15 |
Tandem Diabetes Care, Inc. |
Method and device utilizing insulin delivery protocols
|
UA117480C2
(uk)
|
2013-04-03 |
2018-08-10 |
Санофі |
Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
|
JP2016519127A
(ja)
|
2013-04-30 |
2016-06-30 |
ノヴォ ノルディスク アー/エス |
新規投与レジメン
|
EP3016704A4
(de)
*
|
2013-07-04 |
2017-03-08 |
Insuline Medical Ltd. |
Vorrichtung, system und verfahren zur abgabe eines arzneimittels mit langzeitwirkung
|
KR20160065930A
(ko)
|
2013-10-04 |
2016-06-09 |
머크 샤프 앤드 돔 코포레이션 |
글루코스-반응성 인슐린 접합체
|
AR098168A1
(es)
|
2013-10-25 |
2016-05-04 |
Sanofi Sa |
Formulación estable de insulina glulisina
|
EP3091995B1
(de)
|
2014-01-09 |
2024-03-20 |
Sanofi |
Stabilisierte pharmazeutische formulierungen von insulin aspart
|
BR112016013832A2
(pt)
|
2014-01-09 |
2017-08-08 |
Sanofi Sa |
Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico
|
JP6735674B2
(ja)
*
|
2014-01-09 |
2020-08-05 |
サノフイSanofi |
インスリンアスパルトの安定化された医薬製剤
|
CN106102763A
(zh)
*
|
2014-01-13 |
2016-11-09 |
塞尔玛琳糖尿病有限责任公司 |
速效胰岛素制剂和药物递送***
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
SI3229828T1
(sl)
|
2014-12-12 |
2023-06-30 |
Sanofi-Aventis Deutschland Gmbh |
Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
CN105535942B
(zh)
*
|
2016-01-28 |
2017-07-28 |
通化东宝药业股份有限公司 |
一种赖脯胰岛素硫酸鱼精蛋白制剂的制备方法及其制备的赖脯胰岛素硫酸鱼精蛋白制剂
|
US20210187078A1
(en)
*
|
2016-02-25 |
2021-06-24 |
Wockhardt Limited |
Pharmaceutical composition of insulin glargine and amino acids
|
EP3468562A1
(de)
|
2016-06-10 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Kombinationen aus linagliptin und metformin
|
BR112019011761A2
(pt)
|
2016-12-16 |
2019-11-05 |
Novo Nordisk As |
composições farmacêuticas contendo insulina
|
US10646569B2
(en)
|
2017-05-16 |
2020-05-12 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
PL3474820T3
(pl)
|
2017-08-24 |
2024-05-13 |
Novo Nordisk A/S |
Kompozycje glp-1 i ich zastosowania
|
WO2019125878A1
(en)
|
2017-12-18 |
2019-06-27 |
Merck Sharp & Dohme Corp. |
Conjugate based systems for controlled insulin delivery
|
EP3740212A4
(de)
|
2017-12-18 |
2021-10-27 |
Merck Sharp & Dohme Corp. |
Konjugatbasierte systeme für kontrollierte insulinabgabe
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
CN110063932A
(zh)
*
|
2019-04-12 |
2019-07-30 |
浙江大学 |
一种多肽蛋白类药物的缓释组合物制剂及其制备方法
|
EP4106724A1
(de)
|
2020-02-18 |
2022-12-28 |
Novo Nordisk A/S |
Glp-1-zusammensetzungen und verwendungen davon
|
CR20220555A
(es)
|
2020-03-31 |
2023-01-23 |
Protomer Tech Inc |
Conjugados para reactividad selectiva a dioles vecinales
|
PE20231948A1
(es)
|
2020-11-19 |
2023-12-05 |
Protomer Tech Inc |
Compuestos aromaticos que contienen boro y analogos de insulina
|
WO2023017537A1
(en)
|
2021-08-12 |
2023-02-16 |
Celagenex Research (India) Pvt. Ltd. |
Oral algal oil based gastro-intestinal tract permeable peptide composition
|
WO2023225534A1
(en)
|
2022-05-18 |
2023-11-23 |
Protomer Technologies Inc. |
Aromatic boron-containing compounds and related insulin analogs
|